Vimarsana
Biggest News Aggregation in the World

Page 29 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Boxed Warning Today - Breaking & Trending Today

2023-10-23 | NDAQ:IRWD | Press Release | Ironwood Pharmaceuticals Inc - Vimarsana News

2023-10-23 | NDAQ:IRWD | Press Release | Ironwood Pharmaceuticals Inc

(2023-10-23 | NDAQ:IRWD) Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting - Vimarsana News

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

– Data reinforce the impact of linaclotide on symptoms of IBS-C and CIC – – Additional studies highlight the burden of these disorders on patients – ...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting - Vimarsana News

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from...

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) | Business - Vimarsana News

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) | Business

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis - Vimarsana News

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-ac...